BioPortfolio, June 2, 2007 DURHAM, N.C. -- Thrombotargets, a privately owned biotech company focused on the development of new drug candidates and technologies in the field of hemostasia, today announced the membership of its new scientific advisory board. Members were selected for their expertise on hemostasia, vascular biology, coagulation diseases management, and dental procedure treatment of coagulation disease patients. The new members include: Cam Patterson, M.D., F.A.C.C, the Ernest and Hazel Craige Distinguished Professor of Cardiovascular Medicine, Chief of the Division of Cardiology, at the University of North Carolina, Chapel Hill. He obtained his medical degree from Emory University School of Medicine in 1989 where he served as resident until 1992, and as chief resident, until 1993. He did clinical and research fellowships at the Cardiovascular Biology Laboratory of the Harvard School of Public Health, 1993 to 1996, and later at the Cardiology Section of the University of Texas Medical Branch at Galveston where he served as principal investigator for the Sealy Center for Molecular Cardiology and as associate professor in the Department of Medicine (Cardiology).